Preoperative use of GLP-1 receptor agonists was not significantly associated with short-term postoperative aspiration ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

The news has been littered with stories these days about people losing weight using GLP-1 weight loss drugs like Ozempic. Now ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...